Lupus & antiphospholipid syndrome
Association of galectin-3 in systemic lupus erythematosus: A systematic review and meta-analysis
Pooled result · Circulating galectin-3 levelsResult — go to the resultMean difference 8.48 95% CI 3.84–13.12Authors' conclusion
This meta-analysis depicts that galectin-3 may serve as a biomarker associated with SLE pathogenesis and inflammatory activity due to significantly elevated levels of circulating galectin-3 levels in patients with systemic lupus erythematosus.
Study context
- Population
- Case-control studies reporting circulating galectin-3 levels in individuals with SLE and healthy controlsSeven eligible studies
- Comparison
- Circulating galectin-3 levels in SLE vs healthy controls
- Outcome
- Circulating galectin-3 levels
Methodological detailsNewcastle-Ottawa Scale quality assessment, random-effects not stated, sensitivity analysis, subgroup analysis, Two independent reviewers for selection and data extraction, Databases: PubMed, Scopus, ScienceDirect, Web of Science, Embase; last search September 6, 2025
- Newcastle-Ottawa Scale quality assessment
- Random-effects not stated
- Sensitivity analysis
- Subgroup analysis
- Two independent reviewers for selection and data extraction
- Databases: PubMed, Scopus, ScienceDirect, Web of Science, Embase; last search September 6, 2025
Pooled result
As reported in the abstract
Mean difference
8.48
95% CI 3.84–13.12
P < 0.0001
SLEvs Healthy controls
mean difference 8.48 (95% CI 3.84–13.12); P < 0.0001
Further pooled results
Sensitivity analysis
- Confirmed the stability of the overall findings
Publication bias (Begg's funnel plot, Egger's regression)
- No publication bias
Subgroup analysis
- Supports the results of the overall analysis
Original publication
Association of galectin-3 in systemic lupus erythematosus: A systematic review and meta-analysis. Lupus. Published 8 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →